Anaphylaxis to three humanized antibodies for severe asthma: a case study.
Koichi JingoNorihiro HaradaToshihiko NishiokiMasahiro TorasawaTomoko YamadaTetsuhiko AsaoHaruhi TakagiTomohito TakeshigeJun ItoKazuhisa TakahashiPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)
To our knowledge, this is the first report of an asthmatic patient developing anaphylaxis after commencement of benralizumab, mepolizumab, and omalizumab therapy. These three biologics should be administered carefully, and patients should be monitored for anaphylaxis.